Gastro-enteropancreatic neuroendocrine tumor

A heterogeneous group of tumors that originate in NEUROENDOCRINE CELLS of the embryologic gut; typically the GASTRIC MUCOSA, small or large intestines, rectum, and pancreas.

Also Known As:

GEP neuroendocrine tumor; Gastroenteropancreatic neuroendocrine tumor

Networked: 38 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Disease Context: Research Results

Neoplasms: 1324753
- Neoplasms by Site: 4
  - Digestive System Neoplasms: 236
    - Pancreatic Neoplasms: 34238
      - Gastro-enteropancreatic neuroendocrine tumor: 38
    - Gastrointestinal Neoplasms: 4373
      - Stomach Neoplasms: 50266
        Gastro-enteropancreatic neuroendocrine tumor: 38
      - Intestinal Neoplasms: 523
        Gastro-enteropancreatic neuroendocrine tumor: 38
  - Endocrine Gland Neoplasms: 130
    - Pancreatic Neoplasms: 34238
      - Gastro-enteropancreatic neuroendocrine tumor: 38
- Neoplasms by Histologic Type: 2
  - Germ Cell and Embryonal Neoplasms: 4454
    - Neuroectodermal Tumors: 217
      - Neuroendocrine Tumors: 6270
        Gastro-enteropancreatic neuroendocrine tumor: 38
  - Nerve Tissue Neoplasms: 1
    - Neuroectodermal Tumors: 217
      - Neuroendocrine Tumors: 6270
        Gastro-enteropancreatic neuroendocrine tumor: 38
Digestive System Diseases: 1042
Endocrine System Diseases: 968
- Endocrine Gland Neoplasms: 130
  - Pancreatic Neoplasms: 34238
    - Gastro-enteropancreatic neuroendocrine tumor: 38

Related Diseases

1.	Neuroendocrine Tumors (Neuroendocrine Tumor)
2.	Primitive Neuroectodermal Tumors (PNET)
3.	Neoplasms (Cancer)
4.	Neuroendocrine Carcinoma
5.	Neoplasm Metastasis (Metastasis)

Experts

1.	Strosberg, Jonathan: 2 articles (11/2019 - 09/2016)
2.	Grabowski, Patricia: 2 articles (01/2017 - 01/2005)
3.	Hofland, Leo J: 2 articles (01/2016 - 01/2016)
4.	Kamp, Kimberly: 2 articles (01/2016 - 01/2016)
5.	Kwekkeboom, Dik J: 2 articles (01/2016 - 09/2010)
6.	de Herder, Wouter W: 2 articles (01/2016 - 01/2016)
7.	van Adrichem, Roxanne C S: 2 articles (01/2016 - 01/2016)
8.	Krenning, Eric P: 2 articles (05/2014 - 09/2010)
9.	Chin, Bennett B: 1 article (05/2022)
10.	Grey, Neil: 1 article (05/2022)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Gastro-enteropancreatic neuroendocrine tumor:

1.	Sunitinib (Sutent)FDA Link 01/01/2017 - "Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor." 01/01/2020 - "The Japanese guideline for gastroenteropancreatic neuroendocrine tumor treatment recommends everolimus or sunitinib as first-line treatment for unresectable pancreatic neuroendocrine tumors (PNETs). "
2.	Everolimus FDA Link 01/01/2017 - "Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor." 01/01/2020 - "The Japanese guideline for gastroenteropancreatic neuroendocrine tumor treatment recommends everolimus or sunitinib as first-line treatment for unresectable pancreatic neuroendocrine tumors (PNETs). "
3.	Octreotide (Sandostatin)FDA LinkGeneric 09/01/2019 - "The study objective was to compare overall drug-delivery efficiency between lanreotide and octreotide LAR in gastroenteropancreatic neuroendocrine tumor patients. " 05/01/2014 - "With the aim to improve peptide receptor radionuclide therapy effects in patients with gastroenteropancreatic neuroendocrine tumor (GEPNET) liver metastases we explored the effect of intra-arterial (IA) administration of [(111)In-DTPA]octreotide ((111)In-DTPAOC) on tumor uptake in an animal model and in a patient study. "
4.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/01/2012 - "This study aimed to examine the association between somatostatin receptor-2 positivity and known prognostic factors for gastroenteropancreatic neuroendocrine tumor to identify the value of somatostatin receptor-2 positivity itself as a predictive factor for prognosis. " 09/01/2011 - "It is commonly used in gastroenteropancreatic neuroendocrine tumor (GEP-NET) staging, and represents the criterion of choice for treatment with somatostatin (SST) analogs. " 10/01/2021 - "Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients." 01/01/2012 - "No significant relation was found between somatostatin receptor-2 positivity and any of the known prognostic factors for gastroenteropancreatic neuroendocrine tumor: versus stage, p=0.67; vs. lymph node metastasis, p=0.51; vs. vascular invasion, p=0.11; vs. extension to surrounding soft tissue, p=0.54; vs. necrosis, p=0.23; vs. lymphatic invasion, p=0.25; and vs. perineural invasion, p=0.42. " 01/01/2016 - "Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells."
5.	Peptide Receptors (Peptide Receptor)IBA 10/01/2016 - "To assess the performance of Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic gastroenteropancreatic neuroendocrine tumor (GEP-NET) and correlate it with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. " 10/01/2016 - "Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics." 11/01/2019 - "Introduction: 177Lutetium-[DOTA°,Tyr3]octreotate (177Lu-DOTATATE) is a type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients. " 05/01/2014 - "With the aim to improve peptide receptor radionuclide therapy effects in patients with gastroenteropancreatic neuroendocrine tumor (GEPNET) liver metastases we explored the effect of intra-arterial (IA) administration of [(111)In-DTPA]octreotide ((111)In-DTPAOC) on tumor uptake in an animal model and in a patient study. "
6.	Radioisotopes (Radionuclides)IBA 10/01/2016 - "To assess the performance of Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic gastroenteropancreatic neuroendocrine tumor (GEP-NET) and correlate it with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. " 10/01/2016 - "Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics." 11/01/2019 - "Introduction: 177Lutetium-[DOTA°,Tyr3]octreotate (177Lu-DOTATATE) is a type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients. " 05/01/2014 - "With the aim to improve peptide receptor radionuclide therapy effects in patients with gastroenteropancreatic neuroendocrine tumor (GEPNET) liver metastases we explored the effect of intra-arterial (IA) administration of [(111)In-DTPA]octreotide ((111)In-DTPAOC) on tumor uptake in an animal model and in a patient study. "
7.	lanreotide (Somatuline)FDA Link 01/01/2017 - "When considering preparation and administration time, and real-world dosing, use of lanreotide has the potential to reduce health care expenditures associated with metastatic gastroenteropancreatic neuroendocrine tumor treatments." 09/01/2019 - "The study objective was to compare overall drug-delivery efficiency between lanreotide and octreotide LAR in gastroenteropancreatic neuroendocrine tumor patients. "
8.	Transcription Factors (Transcription Factor)IBA 11/01/2008 - "In the present study, we assessed the expression of transcription factors (NeuroD and mASH1) essential for the normal fetal neuronal development in 33 gastroenteropancreatic neuroendocrine tumor patients (12 well-differentiated neuroendocrine tumors, 7 well-differentiated neuroendocrine carcinomas, and 14 poorly differentiated neuroendocrine carcinomas). "
9.	Pentetic Acid (DTPA)FDA LinkGeneric 05/01/2014 - "With the aim to improve peptide receptor radionuclide therapy effects in patients with gastroenteropancreatic neuroendocrine tumor (GEPNET) liver metastases we explored the effect of intra-arterial (IA) administration of [(111)In-DTPA]octreotide ((111)In-DTPAOC) on tumor uptake in an animal model and in a patient study. "
10.	pasireotideIBA 08/01/2013 - "This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics profiles of pasireotide long-acting release (LAR) formulation in patients with advanced gastroenteropancreatic neuroendocrine tumor (GEP NET) refractory to other SSAs. "

Therapies and Procedures

1.	Therapeutics 12/01/2015 - "Hence, gastroenteropancreatic neuroendocrine tumor is becoming a disease process requiring more of a multi-disciplinary approach with the integration of both locoregional and systemic therapies for improved outcomes. " 11/01/2019 - "[Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy]." 01/01/2017 - "Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy." 09/01/2010 - "Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy." 11/01/2019 - "Surgery combined with regional ablation, endocrine therapy,chemotherapy and targeted therapy presents a favorable prognosis when treated with G1 or G2 gastroenteropancreatic neuroendocrine tumor(GEP-NET). "
2.	Precision Medicine 05/07/2022 - "Finally, we briefly describe the exciting new areas of development and future directions of gastroenteropancreatic neuroendocrine tumor theranostics." 01/01/2016 - "Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era."
3.	Drug Therapy (Chemotherapy) 11/01/2019 - "Surgery combined with regional ablation, endocrine therapy,chemotherapy and targeted therapy presents a favorable prognosis when treated with G1 or G2 gastroenteropancreatic neuroendocrine tumor(GEP-NET). "